{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-277580","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.107737+00:00","generated_at":"2026-05-16T21:17:16.429761+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enliven Q3 net loss $20.1M; cash $477.6M; Phase 1b enrollment completed for ELVN-001","bullets":["Net loss $20.1M in Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M vs $21.3M.","Cash, cash equivalents and marketable securities $477.6M; runway into first half 2029.","Completed randomized Phase 1b portion of ENABLE trial evaluating ELVN-001 in CML patients.","On track to initiate Phase 3 pivotal trial for ELVN-001 in 2026.","Data from ELVN-001 in CML patients with atypical fusion transcripts to be presented at ASH 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-277580","json":"https://secwatch.observer/filing/0001193125-25-277580.json","markdown":"https://secwatch.observer/filing/0001193125-25-277580.md","text":"https://secwatch.observer/filing/0001193125-25-277580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525277580/0001193125-25-277580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525277580/elvn-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:17:16.429761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}